InspireMD
InspireMD's revenue rose 28.1% to $9 million in fiscal 2025. Its operating margin was −552.6%, down from −478.0% a year earlier. Free cash flow was −$37 million. The diluted share count rose 53.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
InspireMD lost money in fiscal 2025: a net loss of $49 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 12 | 5 | 39 | 35 | 54 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 8.5x | 4.2x | 7.3x | 5.3x | 5.7x |
| Quick ratio | 8.3x | 3.9x | 7.0x | 4.9x | 5.4x |
Cash flow
Projections
Project InspireMD's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $420,805 of InspireMD shares on the open market, and 1 insider sold $126,869.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Paul StukaDirector | Bought | 30,000 | $0.58 | $17,400 | Form 4 |
| May 27, 2026 | Paul StukaDirector | Bought | 20,000 | $0.88 | $17,600 | Form 4 |
| May 19, 2026 | Shane Thomas GleasonChief Commercial Officer | Sold | 22,778 | $1.01 | $23,006 | Form 4 |
| May 14, 2026 | Paul StukaDirector | Bought | 5,000 | $1.15 | $5,750 | Form 4 |
| May 13, 2026 | Paul StukaDirector | Bought | 10,000 | $1.16 | $11,600 | Form 4 |
| May 12, 2026 | Marvin SlosmanCEO and President, Director | Bought | 21,000 | $1.20 | $25,200 | Form 4 |
| May 11, 2026 | Paul StukaDirector | Bought plan | 10,000 | $1.19 | $11,900 | Form 4 |
| May 8, 2026 | Paul StukaDirector | Bought plan | 65,626 | $1.16 | $76,126 | Form 4 |
| May 7, 2026 | Gary S RoubinDirector | Bought | 90,000 | $1.18 | $106,200 | Form 4 |
| May 7, 2026 | Scott R. WardDirector | Bought | 73,255 | $1.15 | $84,243 | Form 4 |
| May 7, 2026 | Paul StukaDirector | Bought | 6,378 | $1.15 | $7,335 | Form 4 |
| May 6, 2026 | Scott R. WardDirector | Bought | 15,995 | $1.15 | $18,394 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −250.1% | −319.0% | −381.4% |
| Altman Z'' | −7.79 | −14.33 | −10.12 |
| Accruals ratio | −9.8% | −21.5% | −23.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put InspireMD side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| InspireMD | FY25 | 28.1% | −552.6% | −409.5% | — | — | — | |
| Milestone Scientific | FY25 | 4.0% | −63.5% | −32.7% | — | — | — | Compare |
| Neuroone Medical Technologies | FY25 | 163.5% | −46.5% | −32.1% | — | — | — | Compare |
| Beyond Air | FY26 | 107.3% | −378.2% | −249.6% | — | — | — | Compare |
| Nexgel | FY25 | 31.5% | −29.4% | −12.1% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2 | 3 | 4 | 4 | 2 | 4 | 5 | 6 | 7 | 9 |
| Revenue growth | −18.0% | 45.8% | 30.4% | 3.3% | −33.2% | 80.9% | 15.0% | 20.0% | 13.0% | 28.1% |
| Gross profit | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 3 |
| Research and development | 1 | 1 | 2 | 3 | 2 | 5 | 8 | 8 | 14 | 15 |
| Operating income | −8 | −8 | −8 | −10 | −10 | −15 | −19 | −21 | −34 | −50 |
| Net income | −8 | −8 | −7 | −10 | −10 | −15 | −18 | −20 | −32 | −49 |
| Diluted EPS (US$) | −155,790.00 | −26,235.00 | −250.05 | −72.00 | −6.97 | −2.03 | −2.35 | −0.82 | −0.76 | −0.76 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 2 | 7 | 8 | 24 | 42 | 64 |
| Cash flow | ||||||||||
| Cash from operations | −8 | −8 | −8 | −10 | −9 | −13 | −16 | −16 | −22 | −35 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Free cash flow | −8 | −8 | −8 | −10 | −9 | −14 | −16 | −17 | −23 | −37 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 0 | 0 | 1 | 2 | 2 | 4 | 10 | 12 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 8 | 4 | 9 | 6 | 13 | 12 | 5 | 39 | 35 | 54 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 9 | 6 | 12 | 10 | 18 | 40 | 25 | 48 | 47 | 69 |
| Total liabilities | 5 | 3 | 4 | 4 | 6 | 6 | 7 | 8 | 11 | 14 |
| Shareholders' equity | 4 | 3 | 9 | 5 | 12 | 34 | 17 | 40 | 36 | 55 |
| Margins and ratios | ||||||||||
| Gross margin | 5.4% | 21.2% | 27.6% | 20.3% | 3.3% | 16.8% | 21.6% | 29.1% | 21.5% | 29.5% |
| Operating margin | −403.8% | −298.1% | −211.4% | −263.8% | −417.7% | −327.4% | −361.9% | −340.7% | −478.0% | −552.6% |
| Net margin | −446.7% | −305.6% | −201.1% | −269.8% | −424.3% | −331.9% | −357.6% | −321.0% | −456.6% | −543.3% |
| Free cash flow margin | −398.3% | −303.8% | −213.1% | −271.3% | −369.0% | −301.5% | −309.7% | −270.1% | −332.0% | −409.5% |
| Rule of 40 (growth + FCF margin) | −416.3% | −258.1% | −182.7% | −267.9% | −402.2% | −220.7% | −294.7% | −250.1% | −319.0% | −381.4% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −1,539.8% | −249.2% | −126.0% | −141.9% | −120.2% | −65.3% | −72.6% | −70.0% | −84.7% | −106.9% |
| Return on assets | −112.0% | −108.8% | −78.7% | −90.6% | −76.2% | −51.9% | −57.5% | −55.1% | −67.8% | −84.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |